A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing’s syndrome other than Cushing’s disease-Reference-Cited by-同舟云学术

A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing’s syndrome other than Cushing’s disease

Published:2020 Issue:8 Volume:67 Page:841-852
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Tanaka Tomoaki¹,Satoh Fumitoshi²,Ujihara Makoto³,Midorikawa Sanae⁴,Kaneko Tomomi⁵,Takeda Tamami⁵,Suzuki Akina⁵,Sato Masahiko⁵,Shimatsu Akira⁶

Affiliation:

1. Department of Molecular Diagnosis, Chiba University Hospital/Chiba University Graduate School of Medicine, Chiba 260-8670, Japan

2. Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Hospital, Sendai 980-8574, Japan

3. Department of Internal Medicine, National Hospital Organization Yokohama Medical Center, Yokohama 245-8575, Japan

4. Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan

5. Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan

6. Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555/Advanced Medical Care Center, Kusatsu General Hospital, Kusatsu 525-8585, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/67/8/67_EJ19-0617/_pdf

Reference15 articles.

1. 1 Dekkers OM, Horvath-Puho E, Jorgensen JO, Cannegieter SC, Ehrenstein V, et al. (2013) Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab 98: 2277–2284.

2. 2 Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, et al. (2016) Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol 4: 611–629.

3. 3 Takayanagi R, Miura K, Nakagawa H, Nawata H (2000) Epidemiologic study of adrenal gland disorders in Japan. Biomed Pharmacother 54 Suppl 1: 164s–168s.

4. 4 Porterfield JR, Thompson GB, Young WF Jr, Chow JT, Fryrear RS, et al. (2008) Surgery for Cushing’s syndrome: an historical review and recent ten-year experience. World J Surg 32: 659–677.

5. 5 Valassi E, Franz H, Brue T, Feelders RA, Netea-Maier R, et al. (2017) Diagnostic tests for Cushing’s syndrome differ from published guidelines: data from ERCUSYN. Eur J Endocrinol 176: 613–624.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response to Osilodrostat Therapy in Adrenal Cushing’s Syndrome;Drug, Healthcare and Patient Safety;2024-04

2. A Case of an Ectopic ACTH-Producing Tumor With Adrenal Shrinkage During Osilodrostat Administration;JCEM Case Reports;2024-01-08

3. Cardiovascular risk assessments in patients with cortisol-producing adenoma: impact of clinical features and genetic characteristics;Heart and Vessels;2023-09-11

4. Primary bilateral macronodular adrenal hyperplasia: A series of 32 cases and literature review;Endocrinología, Diabetes y Nutrición (English ed.);2023-04

5. Primary bilateral macronodular adrenal hyperplasia: A series of 32 cases and literature review;Endocrinología, Diabetes y Nutrición;2023-04